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INTRODUCTION 44
Measles remains a major cause of child mortality despite the availability of a safe 45 and effective live attenuated virus vaccine (LAV). Recent efforts to improve routine 46 vaccination and implement national immunization days have moved measles control toward 47 the World Health Assembly goal of 90% reduction in mortality by 2010 compared to 2000 48 (7). One persistent impediment to measles control in many countries remains the inability 49 to successfully immunize young infants due to immaturity of the immune system and 50 interference of maternal antibody with immune responses to LAV (1, 15, 65) . 51
Because waning of maternal antibody varies from one infant to another, many 52 children in areas with high measles virus (MV) transmission are at risk of acquiring 53 measles prior to vaccination (3, 5, 12) . Immaturity also affects the quality and quantity of 54 antibody produced in response to the current vaccine, with lower levels of neutralizing 55 antibody and deficient avidity and isotype maturation in younger compared to older infants 56 (15, 16, 37, 59). As a result, the recommended age for vaccination is generally 9 months in 57 developing countries to balance the risk of infection with the likelihood of response to the 58
vaccine (24). 59
A vaccine that could be given to children under the age of 6 months would improve 60 (Fig. 1C) , but did develop N-specific IgG (Fig. 1E) . Avidity 218 maturation of antibody to H occurred over several months and was similar for animals 219 vaccinated with VEE/SIN-H, VEE/SIN-H+F and LAV (Fig. 1D) . FIMV-vaccinated animals 220
on July 12, 2017 by guest http://jvi.asm.org/ Downloaded from 12 had insufficient H-specific antibody to measure avidity, but had only a modest increase in 221 avidity of N-specific antibody (Fig. 1F) . 222
Vaccine-induced T cell responses in juvenile macaques. To assess the 223 development of MV-specific T cell responses, IFN-and IL-4 production in response to 224 MV H and F peptide stimulation was measured by ELISPOT (Fig. 2) . In general, peak 225 IFN-responses were higher than peak IL-4 responses in all VEE/SIN and LAV-vaccinated 226 monkeys, while FIMV-vaccinated monkeys had numbers of H and F-specific 227 IL-4-producing cells that were similar to the numbers of IFN--producing cells ( Fig. 2A,B) . 228
The highest numbers of IFN--producing cells were present in blood 1-2 weeks after 229 vaccination ( ELISPOT assays. An increase in H-specific IFN-production was detected within 1 month 263 after challenge in all monkeys (Fig. 5A ). Monkeys vaccinated with FIMV showed a later 264 peak (day 25) than VEE/SIN and LAV-vaccinated monkeys (day 7-10). The mean peak 265 numbers of H-specific IFN-producing cells were 98 ± 19 per million PBMC for 266 VEE/SIN-H, 58 ± 19 for VEE/SIN-H+F, 127±12 for FIMV and 100 ± 6 for LAV. 267 F-specific IFN-production was detected in VEE/SIN-H+F, FIMV and LAV-immunized 268 monkeys (Fig. 5B) . The peak numbers of F-specific IFN--producing cells were 22 ± 19 per 269 million PBMC for VEE/SIN-H, 45 ± 13 for VEE/SIN-H+F, 43 ± 1.4 for FIMV and 79±17 270 for LAV. Only FIMV-vaccinated animals showed H and F-specific IL-4 production after 271 challenge with an initial peak at day 20-25 ( Fig. 5C,D) . 272
For monkeys vaccinated with FIMV and VEE/SIN, the T cell responses were 273 biphasic. There was a peak early after challenge that, for FIMV-vaccinated monkeys, 274 coincided with clearance of infectious virus from the blood (Fig. 4A) protective efficacy of the VEE/SIN-H+F replicon particle vaccine in infant monkeys, three 287 1-2 month old rhesus monkeys born to measles-naïve mothers were immunized with 288 VEE/SIN-H+F and boosted 2 months later (Fig. 7) . Infant monkeys showed an increase in 289 PRN antibody by 4 weeks after vaccination, with a maximum at 8 weeks (geometric mean 290 1791 ± 211 mIU/ml), and levels were maintained above 120 mIU/ml for one year (Fig. 7A) . 291 MV-specific IgG OD values were also increased after vaccination and showed a similar 292 pattern to the PRN responses (Fig. 7B) . The mean peak OD reading was 0.78 ± 0.07 (at 293 week 8). H-specific IgG showed a similar pattern (Fig. 7C) and avidity of the antibody to H 294 matured over a time course similar to that of the juvenile monkeys (Figs 1 and 7D) . 295 MV-specific IFN-and IL-4 responses were measured by ELISPOT. Similar to 296 the antibody responses, H-specific IFN--producing T cells appeared by week 4 (Fig. 7E) . 297
Peak H-specific IFN--producing cells were 96 ± 30 SFCs/10 6 PBMCs. F-specific IFN-298 -producing cells were also induced in all vaccinated infant monkeys but were lower than 299 the H response (Fig. 7F) . The peak of the F-specific IFN-SFCs was 38 ± 12 per 10 Protection and immune responses in infant macaques after challenge. To test 302 the protective capacity of VEE/SIN-H+F measles vaccine in infants, monkeys were 303 challenged with wild-type MV one year after vaccination. No monkey developed a rash, 304 viremia or IgM response (data not shown). PRN antibody titers were boosted after 305 challenge to similar levels with a geometric mean peak titer of 2382 ± 1030 (Fig. 8A) . 306 MV-specific IgG measured by EIA also showed a 2-3 fold increase after challenge in all 307 vaccinated monkeys with a peak OD of 1.145 ± 0.493 (Fig. 8B) . MV-specific IFN-, but 308 not IL-4, responses were induced by challenge in all monkeys. The IFN--producing SFCs 309 were 130 ± 47 per 10 6 PBMCs (Fig. 8C) . Similar to H, F-specific IFN-production 310 increased significantly at day 14 with 73 ± 22 SFC/10 6 PBMC (Fig. 8D) . 311
312

DISCUSSION 313
These studies have shown that a single ID injection of a chimeric VEE/SIN 314 replicon particle vaccine expressing the MV H protein or H and F proteins induced 315
long-lasting MV-specific neutralizing antibody and IFN--producing T cells in juvenile 316
rhesus macaques similar to that induced by LAV. Two doses induced similar responses in 317 infant macaques. Vaccination protected both juvenile and infant monkeys from rash and 318 viremia after wild-type MV challenge. A late appearance, without evident accompanying 319 disease, of viral RNA in blood 3 months after challenge in otherwise VEE/SIN-protected 320 on July 12, 2017 by guest http://jvi.asm.org/ Downloaded from monkeys was associated with a renewed increase in circulation of MV-specific T cells and 321 subsequent clearance of viral RNA. We conclude that the chimeric VEE/SIN replicon 322 particle vaccine expressing either H or H and F is a promising candidate for development of 323 a new measles vaccine for infants and that further study of MV infection and clearance in 324 the face of apparent protective immunity is warranted. 
